Literature DB >> 8638391

In vitro responsiveness of Babesia bovis to imidocarb dipropionate and the selection of a drug-adapted line.

R I Rodriguez1, A J Trees.   

Abstract

A South African stock of Babesia bovis was successfully resuscitated from liquid nitrogen, and cultured in microaerophilous stationary phase. The in vitro susceptibility of the B. bovis stock to titrated concentrations of imidocarb dipropionate was observed and the 50% inhibitory concentration (IC) was determined (8.7 x 10(7) g ml-1). A drug-adapted line was developed by culture in the presence of sub-inhibitory concentrations of imidocarb dipropionate and it had an IC50 eight times higher than that of its original stock (6.6 x 10(-6) g ml-1). The drug-adapted line was cryopreserved and resuscitated from liquid nitrogen. Continuous culture of the non-drug adapted line through 15 subcultures did not change the IC50 (8.3 x 10(-7) g ml-1).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638391     DOI: 10.1016/0304-4017(95)00850-0

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  7 in total

1.  In vitro evaluation of drug susceptibilities of Babesia divergens isolates.

Authors:  P Brasseur; S Lecoublet; N Kapel; L Favennec; J J Ballet
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Apicoplast-targeting antibacterials inhibit the growth of Babesia parasites.

Authors:  Mahmoud Aboulaila; Tserendorj Munkhjargal; Thillaiampalam Sivakumar; Akio Ueno; Yuki Nakano; Miki Yokoyama; Takeshi Yoshinari; Daisuke Nagano; Koji Katayama; Nasr El-Bahy; Naoaki Yokoyama; Ikuo Igarashi
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Evaluation of the growth-inhibitory effect of trifluralin analogues on in vitro cultured Babesia bovis parasites.

Authors:  Marta G Silva; Ana Domingos; M Alexandra Esteves; Maria E M Cruz; Carlos E Suarez
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-02-01       Impact factor: 4.077

Review 4.  Current advances in detection and treatment of babesiosis.

Authors:  J Mosqueda; A Olvera-Ramirez; G Aguilar-Tipacamu; G J Canto
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.

Authors:  Siddra A Hines; Joshua D Ramsay; Lowell S Kappmeyer; Audrey Ot Lau; Kayode K Ojo; Wesley C Van Voorhis; Donald P Knowles; Robert H Mealey
Journal:  Parasit Vectors       Date:  2015-01-20       Impact factor: 3.876

6.  Assessment of Draxxin® (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi.

Authors:  Marta G Silva; Nicolas F Villarino; Donald P Knowles; Carlos E Suarez
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-04-17       Impact factor: 4.077

7.  Hap2, a novel gene in Babesia bigemina is expressed in tick stages, and specific antibodies block zygote formation.

Authors:  Minerva Camacho-Nuez; Diego Josimar Hernández-Silva; Elizabeth Jacqueline Castañeda-Ortiz; María Elena Paredes-Martínez; Marisol Karina Rocha-Martínez; María Elizbeth Alvarez-Sánchez; Ricardo Francisco Mercado-Curiel; Gabriela Aguilar-Tipacamu; Juan Mosqueda
Journal:  Parasit Vectors       Date:  2017-11-13       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.